Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of Ataluren in Nonsense Mutation Dystrophinopathy
NCT02090959Phase 3Terminated
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Mar 2014
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 19
01
Overview
A Phase 3 trial of ataluren in Duchenne muscular dystrophy (DMD), sponsored by PTC Therapeutics, Inc.. Started Mar 2014; status: terminated.
02
Drugs
ataluren
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT02090959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02090959.